Mahai Chris LaVictoire 4

What Happened

• Mahai Chris LaVictoire, a director of abrdn Life Sciences Investors (ticker: HQL), made an open-market purchase of 527 shares on July 16, 2026. The shares were acquired at $19.92 per share for a total transaction value of about $10,498. This was a direct purchase (transaction code P), which is generally viewed as a more informative, potentially bullish signal than routine sales.

Key Details

• Transaction date and price: 2026-07-16 — 527 shares at $19.92 each.
• Total value: approximately $10,498.
• Shares owned after transaction: not specified in the information provided.
• Plan or footnotes: no 10b5-1 plan, tax-withholding, or other special footnotes reported in the supplied summary.
• Filing timeliness: Form 4 was filed on 2026-07-20 for the 7/16 transaction; this filing date is within the typical two-business-day deadline and appears timely.

Context

• This was an open-market purchase (not an option exercise, award, or gift), so it represents a direct acquisition of stock by an insider. Purchases by directors can be of interest to investors as a signal that insiders are willing to add to their holdings, but they do not guarantee future performance.